Engineered immune cells take on tough leukemia in kids

NCT ID NCT06709469

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a type of immunotherapy called CAR T cells in children, adolescents, and young adults with acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy involves taking the patient's own immune cells or donor cells, engineering them to better recognize and attack leukemia cells, and infusing them back. The main goal is to see if this approach is safe and feasible, with only 10 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CAR T cells (immune cells engineered to target cancer)
What this could lead to
If successful, this could offer a new treatment option for young patients with leukemia that has not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 10 participants, so safety and feasibility are the main goals. The treatment may cause serious side effects like cytokine release syndrome, and it is not yet known if it will effectively control the disease long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.